http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2580656-C1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be91d5d2c9fd6b88fe042edb134bfbf9 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00 |
filingDate | 2014-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2016-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2016-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2580656-C1 |
titleOfInvention | Immediate-release solid dosage form of hydroxychloroquine and method for producing it |
abstract | FIELD: medicine. n SUBSTANCE: tablet contains hydroxychloroquine sulphate and target additives in the following mixture ratio, wt %: a core: hydroxychloroquine sulphate - 36.24-46.24, calcium hydrogenphosphate dihydrate - 15.59-25.59, hypromellose - 3.0-10.0, croscarmellose sodium - 1.0-7.0, aerosil - 0.5-3.0, stearic acid and/or its salts - 0.5-1.0, Prosolv - the rest; a coating: hypromellose - 0.5-2.5, titanium dioxide - 0.15-0.80, macrogol - 0.05-0.50. Hydroxychloroquine tablets are produced by direct compression. n EFFECT: tablet is characterised by good disintegration and durability, and dissolves quickly; the production of the dosage form is simplified. n 10 cl, 3 tbl |
priorityDate | 2014-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 148.